On Friday, Cardiff Oncology Inc (NASDAQ: CRDF) was 10.33% up from the session before settling in for the closing price of $4.26. A 52-week range for CRDF has been $1.44 – $6.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 20.41%. When this article was written, the company’s average yearly earnings per share was at -6.21%. With a float of $61.33 million, this company’s outstanding shares have now reached $66.52 million.
Let’s determine the extent of company efficiency that accounts for 32 employees. In terms of profitability, gross margin is 55.01%, operating margin of -6735.99%, and the pretax margin is -6239.04%.
Cardiff Oncology Inc (CRDF) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cardiff Oncology Inc stocks. The insider ownership of Cardiff Oncology Inc is 7.80%, while institutional ownership is 27.28%. The most recent insider transaction that took place on Dec 17 ’24, was worth 14,905. In this transaction Chief Financial Officer of this company bought 2,752 shares at a rate of $5.42, taking the stock ownership to the 65,316 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Chief Financial Officer bought 2,400 for $5.00, making the entire transaction worth $12,000. This insider now owns 67,716 shares in total.
Cardiff Oncology Inc (CRDF) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -6.21% per share during the next fiscal year.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
You can see what Cardiff Oncology Inc (CRDF) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 499.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.95, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.98 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Looking closely at Cardiff Oncology Inc (NASDAQ: CRDF), its last 5-days average volume was 1.17 million, which is a drop from its year-to-date volume of 1.54 million. As of the previous 9 days, the stock’s Stochastic %D was 57.13%. Additionally, its Average True Range was 0.46.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 73.53%, which indicates a significant increase from 57.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 170.19% in the past 14 days, which was higher than the 125.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.33, while its 200-day Moving Average is $3.18. However, in the short run, Cardiff Oncology Inc’s stock first resistance to watch stands at $4.86. Second resistance stands at $5.02. The third major resistance level sits at $5.33. If the price goes on to break the first support level at $4.39, it is likely to go to the next support level at $4.08. Should the price break the second support level, the third support level stands at $3.92.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
There are 51,134K outstanding shares of the company, which has a market capitalization of 344.93 million. As of now, sales total 490 K while income totals -41,440 K. Its latest quarter income was 170 K while its last quarter net income were -11,860 K.
